Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.

Wungki ParkLaura MezquitaNaoyuki OkabeYoung Kwang ChaeDeukwoo KwonDiana SaraviaEdouard AuclinDavid PlanchardCaroline CaramellaRoberto FerraraSarita AgteMichael OhRaja MudadMohammad JahanzebHiroyuki SuzukiBenjamin BesseGilberto Lopes

Published in: British journal of cancer (2019)

The iSEND model is associated with the outcome of post-platinum PD-1/L1 monotherapy in advanced NSCLC patients. The iSEND Poor demonstrated a superior performance to PD-L1 = 0% in negative prognostication. Prospective investigation and modelling with other significant parameters in a larger cohort are warranted.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
chronic kidney disease
newly diagnosed
combination therapy
open label
prognostic factors
peritoneal dialysis
clinical trial
randomized controlled trial